search
Back to results

Dietary Supplement of LEHEL for the Patients With Type 2 Diabetes

Primary Purpose

Type 2 Diabetes

Status
Completed
Phase
Early Phase 1
Locations
China
Study Type
Interventional
Intervention
LEHEL multi-nutrients supplement
Sponsored by
Shaoguan University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type 2 Diabetes focused on measuring Malnutrition; Metabolic disorders

Eligibility Criteria

25 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Subject is diagnosed with type 2 diabetes mellitus according to the Chinese type 2 diabetes prevention guide 2010, diagnostic criteria are as follows:

    (1) Diabetes symptoms(polydipsia、polyphagia, polyuria, weight loss、skin itching、blurred vision and other acute metabolic network disorder that caused by high blood sugar)combined with random blood sugar ≥11.1 OR, (2) fasting plasma glucose (FPG) ≥7.0 OR, (3) 2 h blood sugar after oral glucose tolerance test (OGTT) ≥11.1;

  • Subject is between 18 and 75 years of age, inclusive.
  • Subject's BMI is >18.5 kg/m2 and <35 kg/m2.
  • If on a chronic medication such as anti-hypertensive, lipid-lowering, thyroid medication or hormone therapy, subject has been on constant dosage for at least two months prior to screening visit.

Exclusion Criteria:

  • Subject that is diagnosed as type 1 diabetes, gestational diabetes and other kinds of diabetes expect type 2.
  • Subject that use exogenous insulin for glucose control.
  • Subject that has a history of diabetic ketoacidosis.
  • Subject that has mental disorder, cancer, cirrhosis, renal disease and hepatic disease.
  • Subject that has had a significant cardiovascular event less than six months prior to screening visit or has history of congestive heart failure.
  • Subject that has had operation less than six months prior to screening visit.
  • Subject that has taken/is currently taking any dietary supplements or medications that could profoundly affect blood glucose during the past one month prior to screening visit.
  • Subject is known to be allergic or intolerant to any ingredient found in the study product.

Sites / Locations

  • Shaoguan University

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

LEHEL multi-nutrients supplement

Control

Arm Description

75 g/d of LEHEL supplementation along with oral hypoglycemic agents such as glibenclamide and/or metformin.

Received only oral hypoglycemic agents.

Outcomes

Primary Outcome Measures

Metabolic Control
Hemoglobin A1c (HbA1c) and lipids (Cholesterol, HDL-cholesterol, Triglycerides) at study entry and 12 weeks after dietary intervention

Secondary Outcome Measures

Full Information

First Posted
September 7, 2013
Last Updated
May 8, 2014
Sponsor
Shaoguan University
Collaborators
Sun Yat-sen University
search

1. Study Identification

Unique Protocol Identification Number
NCT01940302
Brief Title
Dietary Supplement of LEHEL for the Patients With Type 2 Diabetes
Official Title
Metabolic Control Before and After Supplementation With LEHEL in Patients With Type 2 Diabetes
Study Type
Interventional

2. Study Status

Record Verification Date
May 2014
Overall Recruitment Status
Completed
Study Start Date
June 2013 (undefined)
Primary Completion Date
December 2013 (Actual)
Study Completion Date
March 2014 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Shaoguan University
Collaborators
Sun Yat-sen University

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Due to metabolic disorders and dietary restrictions, patients with diabetes may have different degrees of malnutrition. The primary objective of this study is to investigate whether supplementation of LEHEL, a multi-nutrients supplement, is capable to improve metabolic parameters in patients with type 2 diabetes.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes
Keywords
Malnutrition; Metabolic disorders

7. Study Design

Primary Purpose
Treatment
Study Phase
Early Phase 1
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
71 (Actual)

8. Arms, Groups, and Interventions

Arm Title
LEHEL multi-nutrients supplement
Arm Type
Experimental
Arm Description
75 g/d of LEHEL supplementation along with oral hypoglycemic agents such as glibenclamide and/or metformin.
Arm Title
Control
Arm Type
No Intervention
Arm Description
Received only oral hypoglycemic agents.
Intervention Type
Dietary Supplement
Intervention Name(s)
LEHEL multi-nutrients supplement
Intervention Description
The primary objective of this study is to evaluate the effect of a diet program including LEHEL multi-nutrients supplement as breakfast replacement on metabolic control after 12-week intervention in subjects with type 2 diabetes.
Primary Outcome Measure Information:
Title
Metabolic Control
Description
Hemoglobin A1c (HbA1c) and lipids (Cholesterol, HDL-cholesterol, Triglycerides) at study entry and 12 weeks after dietary intervention
Time Frame
Twelve weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
25 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Subject is diagnosed with type 2 diabetes mellitus according to the Chinese type 2 diabetes prevention guide 2010, diagnostic criteria are as follows: (1) Diabetes symptoms(polydipsia、polyphagia, polyuria, weight loss、skin itching、blurred vision and other acute metabolic network disorder that caused by high blood sugar)combined with random blood sugar ≥11.1 OR, (2) fasting plasma glucose (FPG) ≥7.0 OR, (3) 2 h blood sugar after oral glucose tolerance test (OGTT) ≥11.1; Subject is between 18 and 75 years of age, inclusive. Subject's BMI is >18.5 kg/m2 and <35 kg/m2. If on a chronic medication such as anti-hypertensive, lipid-lowering, thyroid medication or hormone therapy, subject has been on constant dosage for at least two months prior to screening visit. Exclusion Criteria: Subject that is diagnosed as type 1 diabetes, gestational diabetes and other kinds of diabetes expect type 2. Subject that use exogenous insulin for glucose control. Subject that has a history of diabetic ketoacidosis. Subject that has mental disorder, cancer, cirrhosis, renal disease and hepatic disease. Subject that has had a significant cardiovascular event less than six months prior to screening visit or has history of congestive heart failure. Subject that has had operation less than six months prior to screening visit. Subject that has taken/is currently taking any dietary supplements or medications that could profoundly affect blood glucose during the past one month prior to screening visit. Subject is known to be allergic or intolerant to any ingredient found in the study product.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Wenhua Ling, Ph.D.
Organizational Affiliation
Sun Yat-sen University
Official's Role
Study Director
Facility Information:
Facility Name
Shaoguan University
City
Shaoguan
State/Province
Guangdong
ZIP/Postal Code
512005
Country
China

12. IPD Sharing Statement

Learn more about this trial

Dietary Supplement of LEHEL for the Patients With Type 2 Diabetes

We'll reach out to this number within 24 hrs